<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984256</url>
  </required_header>
  <id_info>
    <org_study_id>WRAIR 1583</org_study_id>
    <secondary_id>HSRRB # A-15648</secondary_id>
    <nct_id>NCT00984256</nct_id>
  </id_info>
  <brief_title>Weekly Dosing of Malarone 速 for Prevention of Malaria</brief_title>
  <acronym>MALWEEK</acronym>
  <official_title>Pilot Evaluation of Weekly Dosing of Atovaquone/Proguanil (Malarone 速) for Malaria Chemoprophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Malarone 速, which is a drug approved to
      prevent malaria when taken daily, will still effectively prevent malaria if taken weekly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, two groups of volunteers will be exposed to malaria through the bites of
      infected mosquitoes. In one group, volunteers will be randomly assigned to one of 5 arms.
      Each of these arms will receive a different dose of Malarone速, a drug known to prevent
      malaria when taken daily. Each of these doses will be lower than the maximum approved dose of
      this medicine. The other group will not be treated with any drug that could prevent symptoms
      or infection.

      After exposure, both groups will be monitored for a period of approximately 3 months to see
      if they develop symptoms of malaria. Any subjects who do so will be treated with appropriate
      medications. Subjects in both groups will have their blood checked regularly during this
      period for the presence of malaria parasites. At the completion of the study, results will be
      analyzed to determine whether any of the doses of Malarone might effectively prevent malaria
      if taken weekly rather than daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prophylactic Efficacy of 3 Different Doses of Atovaquone/Proguanil (Malarone@) Given 1 Week Before Infectious Sporozoite Challenge Using the P. Falciparum Human Challenge Model.</measure>
    <time_frame>Days 6-20</time_frame>
    <description>Number of participants with prophylactic efficacy was determined by the absence of cases of malaria parasitemia, defined as microscopically detectable parasitemia by Giemsa-stained thick smears, in those receiving any dose of Malarone as compared to the control (no treatment) group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measured Concentrations of Plasma Atovaquone With Determinations of T1/2.</measure>
    <time_frame>7, 6, 5, and 1 day prior to challenge; on the day of the challenge; 1, 4, 5, 6, 7, 8, 10and 14 days after the challenge; and on the day parasitemia develops.,</time_frame>
    <description>Plasma concentrations (ng/ml) were used to determine the elimination half life (t1/2) of atovaquone (days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured Concentrations of Plasma Atovaquone With Determinations of Area Under the Curve</measure>
    <time_frame>7, 6, 5, and 1 day prior to challenge; on the day of the challenge; 1, 4, 5, 6, 7, 8, 10and 14 days after the challenge; and on the day parasitemia develops.,</time_frame>
    <description>Plasma concentrations were used to determine the pharmacokinetic curves with determinations of area under the curve (AUC).The smallest AUC Day 0-6.5 associated with protection from detectable parasitemia, and the highest AUC Day 0-6.5 observed in any cases of malaria (prophylactic failures) were to be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 groups, each group receiving Malarone tablet(s) (250/100mg)prior to challenge.
Group 1 - 1 tablet 1 day before challenge Group 2 - 1 tablet 4 days before challenge Group 3 - 1 tablet 7 days before challenge Group 4 - 2 tablets 7 days before challenge Group 5 - 4 tablets 7 days before challenge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control -no prophylaxis</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atovaquone Proguanil</intervention_name>
    <description>Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.</description>
    <arm_group_label>Drug</arm_group_label>
    <other_name>Malaria</other_name>
    <other_name>Prophylaxis</other_name>
    <other_name>Atovaquone</other_name>
    <other_name>Malarone</other_name>
    <other_name>Challenge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Procedure - malaria challenge</intervention_name>
    <description>2) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.</description>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_label>Control -no prophylaxis</arm_group_label>
    <other_name>Malaria</other_name>
    <other_name>Prophylaxis</other_name>
    <other_name>Atovaquone</other_name>
    <other_name>Malarone</other_name>
    <other_name>Challenge</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the
             time of screening

          -  Free of clinically significant health problems

          -  Baseline ECG before entering into the study

          -  Available to participate for duration of study (approximately 4 months, not including
             screening period)

          -  If the participant is female, not pregnant or lactating and willing to use
             contraception to prevent pregnancy

          -  BMI between 19 and 30

        Exclusion Criteria:

          -  History of malaria or travel to a malarious country within the previous 12 months

          -  History of participation in a study in which potential exposure to malaria or
             vaccination against malaria occurred.

          -  Planned travel to malarious areas during the study period.

          -  History of malaria chemoprophylaxis within 60 days prior to time of study entry.

          -  Chronic use of antibiotics with anti-malarial effects

          -  Chronic use (defined as more than 14 days)of immunosuppressants or other
             immune-modifying drugs within six months of study entry.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination, ECG or laboratory
             screening tests

          -  Significant unexplained anemia

          -  History of sickle cell disease or sickle cell trait

          -  Seropositive for hepatitis B or hepatitis C

          -  History of splenectomy

          -  Pregnant or lactating female, or female who intends to become pregnant during the
             study

          -  Suspected or known current alcohol abuse as defined by the American Psychiatric
             Association in DSM IV

          -  History of a neuropsychiatric disorder (anxiety, depression, psychosis, schizophrenia)

          -  Chronic or active illicit and/or intravenous drug use

          -  History of allergy to atovaquone, proguanil or chloroquine

          -  History of psoriasis

          -  Concurrent participation in other research studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Deye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Institute of Research (WRAIR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Institute of Research</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Deye GA, Miller RS, Miller L, Salas CJ, Tosh D, Macareo L, Smith BL, Fracisco S, Clemens EG, Murphy J, Sousa JC, Dumler JS, Magill AJ. Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. Clin Infect Dis. 2012 Jan 15;54(2):232-9. doi: 10.1093/cid/cir770. Epub 2011 Nov 3.</citation>
    <PMID>22052893</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <results_first_submitted>September 4, 2012</results_first_submitted>
  <results_first_submitted_qc>October 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2013</results_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Atovaquone</keyword>
  <keyword>Malarone</keyword>
  <keyword>Challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atovaquone, proguanil drug combination</mesh_term>
    <mesh_term>Atovaquone</mesh_term>
    <mesh_term>Proguanil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study subjects were healthy male and non-pregnant or lactating females between the ages of 18 and 50 with a body mass index (BMI)between 19 and 30 for subject receiving the drug.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>The six volunteers in control cohort were enrolled as infectivity controls and did not undergo randomization or receive any study drug.</description>
        </group>
        <group group_id="P2">
          <title>Malarone Treatment</title>
          <description>Within the Malarone Arm, thirty volunteers were randomized into the below 5 treatment groups, each group receiving Malarone tablet(s) (250/100mg)prior to challenge.
Group 1 - 1 tablet 1 day before challenge Group 2 - 1 tablet 4 days before challenge Group 3 - 1 tablet 7 days before challenge Group 4 - 2 tablets 7 days before challenge Group 5 - 4 tablets 7 days before challenge</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>one subject withdrew consent</population>
      <group_list>
        <group group_id="B1">
          <title>Malarone</title>
          <description>Thirty (30) subjects were placed in the Malarone (treatment) Arm. The thirty subjects were then randomized into 5 treatment groups, each group receiving Malarone tablet(s) (250/100mg)prior to challenge. The groups received treatment as follows:
Group 1 - 1 tablet 1 day before challenge Group 2 - 1 tablet 4 days before challenge Group 3 - 1 tablet 7 days before challenge Group 4 - 2 tablets 7 days before challenge Group 5 - 4 tablets 7 days before challenge</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>The six (6) Control volunteers were enrolled in a open label arm and received no treatment prior to malaria challenge.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prophylactic Efficacy of 3 Different Doses of Atovaquone/Proguanil (Malarone@) Given 1 Week Before Infectious Sporozoite Challenge Using the P. Falciparum Human Challenge Model.</title>
        <description>Number of participants with prophylactic efficacy was determined by the absence of cases of malaria parasitemia, defined as microscopically detectable parasitemia by Giemsa-stained thick smears, in those receiving any dose of Malarone as compared to the control (no treatment) group</description>
        <time_frame>Days 6-20</time_frame>
        <population>Analysis population was &quot;According to Protocol&quot; which included participants meeting all eligibility criteria, not meeting any elimination criteria, complying with defined protocol procedures and for whom data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group 1</title>
            <description>(Group 1) Malarone 1 tablet (250/100 mg) orally administered once 1 day prior to challenge</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group 2</title>
            <description>(Group 2) Malarone 1 tablet (250/100 mg) orally administered once on day 4 after challenge</description>
          </group>
          <group group_id="O3">
            <title>Treatment Group 3</title>
            <description>(Group 3) Malarone 1 tablets (250/100 mg) orally administered once 7 days prior to challenge</description>
          </group>
          <group group_id="O4">
            <title>Treatment Group 4</title>
            <description>(Group 4) Malarone 2 tablets (500/200 mg) orally administered once 7 days prior to challenge</description>
          </group>
          <group group_id="O5">
            <title>Treatment Group 5</title>
            <description>(Group 5) Malarone 4 tablets (1000/400 mg) orally administered once 7 days prior to challenge</description>
          </group>
          <group group_id="O6">
            <title>Control</title>
            <description>Six volunteers for the control cohort were enrolled as an infectivity control and did not undergo drug dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Prophylactic Efficacy of 3 Different Doses of Atovaquone/Proguanil (Malarone@) Given 1 Week Before Infectious Sporozoite Challenge Using the P. Falciparum Human Challenge Model.</title>
          <description>Number of participants with prophylactic efficacy was determined by the absence of cases of malaria parasitemia, defined as microscopically detectable parasitemia by Giemsa-stained thick smears, in those receiving any dose of Malarone as compared to the control (no treatment) group</description>
          <population>Analysis population was &quot;According to Protocol&quot; which included participants meeting all eligibility criteria, not meeting any elimination criteria, complying with defined protocol procedures and for whom data are available.</population>
          <units>participants with negative parasitemia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measured Concentrations of Plasma Atovaquone With Determinations of T1/2.</title>
        <description>Plasma concentrations (ng/ml) were used to determine the elimination half life (t1/2) of atovaquone (days).</description>
        <time_frame>7, 6, 5, and 1 day prior to challenge; on the day of the challenge; 1, 4, 5, 6, 7, 8, 10and 14 days after the challenge; and on the day parasitemia develops.,</time_frame>
        <population>Population for analysis included According to Protocol Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis Group 1</title>
            <description>(Group 1) Malarone 1 tablet (250/100 mg) orally administered once 1 day prior to challenge</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Group 2</title>
            <description>(Group 2) Malarone 1 tablet (250/100 mg) orally administered once on day 4 after challenge</description>
          </group>
          <group group_id="O3">
            <title>Prophylaxis Group 3</title>
            <description>(Group 3)Malarone 1 tablets (250/100 mg) orally administered once 7 days prior to challenge</description>
          </group>
          <group group_id="O4">
            <title>Prophylaxis Group 4</title>
            <description>(Group 4) Malarone 2 tablets (500/200 mg) orally administered once 7 days prior to challenge</description>
          </group>
          <group group_id="O5">
            <title>Prophylaxis Group 5</title>
            <description>(Group 5) Malarone 4 tablets (1000/400 mg) orally administered once 7 days prior to challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Measured Concentrations of Plasma Atovaquone With Determinations of T1/2.</title>
          <description>Plasma concentrations (ng/ml) were used to determine the elimination half life (t1/2) of atovaquone (days).</description>
          <population>Population for analysis included According to Protocol Population.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.9"/>
                    <measurement group_id="O2" value="3.3" spread="1.2"/>
                    <measurement group_id="O3" value="3.3" spread="1.6"/>
                    <measurement group_id="O4" value="5.6" spread="3.1"/>
                    <measurement group_id="O5" value="3.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measured Concentrations of Plasma Atovaquone With Determinations of Area Under the Curve</title>
        <description>Plasma concentrations were used to determine the pharmacokinetic curves with determinations of area under the curve (AUC).The smallest AUC Day 0-6.5 associated with protection from detectable parasitemia, and the highest AUC Day 0-6.5 observed in any cases of malaria (prophylactic failures) were to be reported.</description>
        <time_frame>7, 6, 5, and 1 day prior to challenge; on the day of the challenge; 1, 4, 5, 6, 7, 8, 10and 14 days after the challenge; and on the day parasitemia develops.,</time_frame>
        <population>Analysis was done on subjects who completed the study according to protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group 1</title>
            <description>(Group 1) Malarone 1 tablet (250/100 mg) orally administered once 1 day prior to challenge</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group 2</title>
            <description>(Group 2) Malarone 1 tablet (250/100 mg) orally administered once on day 4 after challenge</description>
          </group>
          <group group_id="O3">
            <title>Treatment Group 3</title>
            <description>(Group 3) Malarone 1 tablets (250/100 mg) orally administered once 7 days prior to challenge</description>
          </group>
          <group group_id="O4">
            <title>Treatment Group 4</title>
            <description>(Group 4) Malarone 2 tablets (500/200 mg) orally administered once 7 days prior to challenge</description>
          </group>
          <group group_id="O5">
            <title>Treatment Group 5</title>
            <description>(Group 5) Malarone 4 tablets (1000/400 mg) orally administered once 7 days prior to challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Measured Concentrations of Plasma Atovaquone With Determinations of Area Under the Curve</title>
          <description>Plasma concentrations were used to determine the pharmacokinetic curves with determinations of area under the curve (AUC).The smallest AUC Day 0-6.5 associated with protection from detectable parasitemia, and the highest AUC Day 0-6.5 observed in any cases of malaria (prophylactic failures) were to be reported.</description>
          <population>Analysis was done on subjects who completed the study according to protocol</population>
          <units>ng*day/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3595" spread="2213"/>
                    <measurement group_id="O2" value="616" spread="191"/>
                    <measurement group_id="O3" value="510" spread="218"/>
                    <measurement group_id="O4" value="1434" spread="664"/>
                    <measurement group_id="O5" value="2233" spread="1895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days before challenge until end of the study (Day 90)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Drug</title>
          <description>Partially randomized, double-blind, placebo-controlled trial using a human Plasmodium falciparum challenge to evaluate malaria chemoprophylaxis of Malarone in 36 healthy adults. Subjects were enrolled in 1 of 2 cohorts based on subject preference. Thirty subjects were placed in the prophylaxis cohort (Cohort 1) and 6 subjects were placed in the control cohort (Cohort 2)
5 treatment groups, each group receiving Malarone tablet(s) (250/100mg)prior to challenge.
Group 1 - 1 tablet 1 day before challenge Group 2 - 1 tablet 4 days before challenge Group 3 - 1 tablet 7 days before challenge Group 4 - 2 tablets 7 days before challenge Group 5 - 4 tablets 7 days before challenge</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>no malarone prophylaxis received</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache was the most common event</description>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michelle Mathers</name_or_title>
      <organization>US Army Medical Materiel Development Activity (USAMMDA)</organization>
      <phone>301-619-8061</phone>
      <email>Michelle.mathers@us.army.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

